Formulation of Aceclofenac Tablets Using Nanosuspension as Granulating Agent: An Attempt to Enhance Dissolution Rate and Oral Bioavailability.


Journal

International journal of nanomedicine
ISSN: 1178-2013
Titre abrégé: Int J Nanomedicine
Pays: New Zealand
ID NLM: 101263847

Informations de publication

Date de publication:
2020
Historique:
received: 06 07 2020
accepted: 07 10 2020
entrez: 25 11 2020
pubmed: 26 11 2020
medline: 22 12 2020
Statut: epublish

Résumé

The aim of the studies was to fabricate aceclofenac (AC) tablets using nanosuspension as granulating fluid to boost its rate of in vitro dissolution and eventually its oral bioavailability. The optimized nanosuspension with particle size of 112±2.01 nm was fabricated using HPMC 1% (w/v), PVP-K30 1% (w/v) and SLS 0.12% (w/v) at 400 watts of ultrasonication energy for 15 min duration and 3 sec pause. Then, the optimized aceclofenac nanosuspension was used as granulating fluid for aceclofenac tablets formulation. The characterization was performed using Malvern zetasizer, SEM, TEM, DSC and P-XRD. The granules were evaluated for the bulk and tapped densities, Hausner's ratio, angle of repose and their resulted values were found within limit. The prepared tablets were tested for average weight, hardness, friability, disintegration, dissolution and in vivo bioavailability in rabbits. The in vitro dissolution data showed the boosted rate of nanosuspension-based tablets compared to the microsuspension-based tablets. The in vivo bioavailability (in rabbits model) of aceclofenac nanosuspension-based tablets (ACN-1, ACN-2) proved an improved absorption as in comparison to the marketed formulation. The C This boosted in vitro and in vivo bioavailability may be attributed to reduced particle size of aceclofenac nanoformulations used in tablets. Finally, this will result in faster absorption of these fabricated tablets.

Identifiants

pubmed: 33235448
doi: 10.2147/IJN.S270746
pii: 270746
pmc: PMC7680606
doi:

Substances chimiques

Suspensions 0
Tablets 0
Diclofenac 144O8QL0L1
aceclofenac RPK779R03H

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

8999-9009

Informations de copyright

© 2020 Rahim et al.

Déclaration de conflit d'intérêts

Umar Farooq is an employee of Legacy Pharmaceutical (Pvt.) Ltd. The authors report no other potential conflicts of interest for this work.

Références

Pharmaceutics. 2018 Jul 08;10(3):
pubmed: 29986543
Pak J Pharm Sci. 2015 May;28(3):909-14
pubmed: 26004724
Drug Discov Today. 2018 Mar;23(3):534-547
pubmed: 29326082
Int J Nanomedicine. 2013;8:3119-28
pubmed: 23983465
AAPS PharmSciTech. 2003 Dec 12;4(4):E61
pubmed: 15198556
Pharm Res. 2008 Oct;25(10):2334-44
pubmed: 18560998
Int J Pharm. 2006 Aug 31;320(1-2):23-9
pubmed: 16759826
Int J Pharm. 2014 Oct 20;474(1-2):146-50
pubmed: 25138256
Res Pharm Sci. 2015 Mar-Apr;10(2):95-108
pubmed: 26487886
J Control Release. 2011 Jan 20;149(2):175-81
pubmed: 20946923
Int J Pharm. 2008 Feb 28;350(1-2):279-90
pubmed: 17945447
J Colloid Interface Sci. 2008 Sep 15;325(2):404-13
pubmed: 18561941
Ultrason Sonochem. 2007 Sep;14(6):717-24
pubmed: 17254828
AAPS PharmSciTech. 2008;9(1):250-8
pubmed: 18446489
ILAR J. 1997;38(1):41-48
pubmed: 11528046
Eur J Pharm Sci. 2013 Jul 16;49(4):565-77
pubmed: 23587645
Eur J Pharm Biopharm. 2006 Jun;63(2):173-5
pubmed: 16621482
Toxicol Pathol. 2008 Jan;36(1):43-8
pubmed: 18337220
J Pharm Pharmacol. 2004 Jul;56(7):827-40
pubmed: 15233860
Drug Dev Ind Pharm. 2004 May;30(5):525-34
pubmed: 15244088
Int J Nanomedicine. 2019 Aug 06;14:6287-6296
pubmed: 31496686
Drug Des Devel Ther. 2019 Nov 28;13:4007-4020
pubmed: 31819372
Eur J Pharm Sci. 2010 Jul 11;40(4):325-34
pubmed: 20417274
Drug Des Devel Ther. 2017 Aug 23;11:2443-2452
pubmed: 28860715

Auteurs

Haroon Rahim (H)

Department of Pharmacy, Sarhad University of Science and Information Technology, Peshawar, Khyber Pakhtunkhwa, Pakistan.

Abdul Sadiq (A)

Department of Pharmacy, University of Malakand, Chakdara, Khyber Pakhtunkhwa, Pakistan.

Riaz Ullah (R)

Department of Pharmacognosy (MAPPRC), College of Pharmacy, King Saud University Riyadh, Riyadh, Saudi Arabia.

Ahmed Bari (A)

Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University Riyadh, Riyadh, Saudi Arabia.

Fazli Amin (F)

Department of Pharmacy, Sarhad University of Science and Information Technology, Peshawar, Khyber Pakhtunkhwa, Pakistan.

Umar Farooq (U)

Legacy Pharmaceutical (Pvt.) Ltd., Peshawar, Khyber Pakhtunkhwa, Pakistan.

Naeem Ullah Jan (N)

Department of Pharmacy, Sarhad University of Science and Information Technology, Peshawar, Khyber Pakhtunkhwa, Pakistan.

Hafiz Majid Mahmood (HM)

Department of Pharmacology, College of Pharmacy, King Saud University Riyadh, Riyadh, Saudi Arabia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs
Humans Meals Time Factors Female Adult

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Classifications MeSH